Phoenix Biosciences
Phoenix Biosciences is younger than twelve months; there is no public track record yet to compute a bankruptcy probability from. The 2025 annual accounts show equity of €3.68M and a net result of €-2.81M. Its solvency ranks better than 47% of 81 sector peers (fiscal year 2025). The company has been active since 2025 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €3.68M |
| Net result | €-2.81M |
| Staff (FTE) | 8.3 |
| Better than sector | 47% |
Mixed profile: strong on solvency, weaker on profitability.
This company is younger than 12 months. There is no public track record yet to base a reliable estimate on, so we'd rather not show a number.
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 45.4% | 49.8% | |
| Net result | €-2.81M | €17k | |
| Equity | €3.68M | €102k | |
| Total assets | €8.11M | €250k |
| Fiscal year | 2025 |
|---|---|
| Revenue | €1.30M |
| EBITDA | €-2.75M |
| Net profit | €-2.81M |
| Cash flow | €-2.76M |
| Staff costs | €957k |
| Income taxes | - |
| Dividends | - |
| Total assets | €8.11M |
| Equity | €3.68M |
| Debt | €4.43M |
| of which ≤ 1y | €1.40M |
| of which > 1y | €3.00M |
| Working capital | €5.38M |
| Employees (FTE) | 8.3 |
| 2025 | |
|---|---|
| Current ratio | 4.83 |
| Quick ratio | 4.36 |
| Working capital ratio | 66.4% |
| Solvency | 45.4% |
| Debt / equity | 1.20 |
| Long-term debt ratio | 0.81 |
| Interest coverage | -385.68 |
| Gross margin | 89.9% |
| Net margin | -216.6% |
| ROA | -34.6% |
| ROE | -76.3% |
| EBITDA margin | -211.6% |
| Days sales outstanding | 351d |
| Days payable outstanding | 1383d |
| Inventory turnover | 0.20 |
| Days inventory (DSI) | 1840d |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €8.11M |
| Fixed assets | 21/28 | €1.32M |
| Intangible fixed assets | 21 | €1.10M |
| Tangible fixed assets | 22/27 | €166k |
| Financial fixed assets | 28 | €54k |
| Current assets | 29/58 | €6.79M |
| Stocks & contracts in progress | 3 | €663k |
| Amounts receivable within one year | 40/41 | €1.46M |
| Cash & bank | 54/58 | €4.65M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €8.11M |
| Equity | 10/15 | €3.68M |
| Contributions / capital | 10/11 | €6.49M |
| Accumulated profits (losses) | 14 | €-2.81M |
| Amounts payable | 17/49 | €4.43M |
| Amounts payable after one year | 17 | €3.00M |
| Amounts payable within one year | 42/48 | €1.40M |
| Trade debts payable within one year | 44 | €498k |
| Income statement | ||
| Turnover | 70 | €1.30M |
| Operating result | 9901 | €-2.80M |
| Financial income | 75 | €218 |
| Financial charges | 65 | €11k |
| Result before taxes | 9903 | €-2.81M |
| Net result for the period | 9904 | €-2.81M |
| Result to be appropriated | 9905 | €-2.81M |
-
GFB ConsultLegal entityDirector· perm. rep.: BOONEN Geoffroy Isabelle Patrick Marie GustaveState Gazette act 25378319 (18-12-2025)Current12-12-2025 → present
-
Current12-12-2025 → present
-
Current31-10-2025 → present
Former directors (1)
-
Former- → 31-10-2025
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISESCurrent Statutory auditor · represented by Rodrigo Abels |
- | 12-12-2025 → present |
| Pierre Warzée Réviseur d'entreprisesCurrent Company auditor · represented by Pierre Warzée |
- | 31-10-2025 → present |
| NACE primary | 72101 |
| Legal form | Public limited company(014) |
| Incorporation | 15-09-2025 |
| Status | Active |
| Postal code | 1400 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25099D0025/00L003 | Wallonia | 3,517 m² | 1 · 1,386 m² | 7.0 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
18-12-2025 Capital increase of €12,903 to €110,715
- €97.812 → €110.715
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 12903,
"currency": "EUR",
"after_eur": 110715,
"delta_eur": 12903,
"before_eur": 97812,
"amount_type": "kapitaal_effectief",
"effective_date": "2025-12-12",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital de la Soci\u00E9t\u00E9 \u00E0 concurrence de 12.903 EUR, pour le porter de 97.812 EUR \u00E0 110.715 EUR.",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "1027.640.071",
"name_full": "PHOENIX BIOSCIENCES",
"legal_form": "SA"
}
}13-11-2025 Capital increase of €36,312 to €97,812
- €61.500 → €97.812
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 36312.0,
"currency": "EUR",
"after_eur": 97812.0,
"delta_eur": 36312.0,
"before_eur": 61500.0,
"amount_type": "kapitaal_effectief",
"effective_date": "2025-10-31",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital de la Soci\u00E9t\u00E9 \u00E0 concurrence de 36.312,00 EUR, pour le porter de 61.500,00 EUR \u00E0 97.812,00 EUR, par l\u0027\u00E9mission de 36.312 actions ordinaires... L\u0027assembl\u00E9e d\u00E9cide que l\u0027augmentation du capital sera r\u00E9alis\u00E9e par l\u2019apport par les actionnaires et souscripteurs... d\u2019une cr\u00E9ance certaine, liquide et exigible",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "1027.640.071",
"name_full": "PHOENIX BIOSCIENCES",
"legal_form": "SA"
}
}15-10-2025 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "1027.640.071",
"name_full": "PHOENIX BIOSCIENCES",
"legal_form": "SA"
}
}17-09-2025 Incorporation of a new SNC
Technical details
{
"kind": "oprichting",
"seat": "1400 Nivelles, Rue de la Ma\u00EEtrise 11",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1966-03-01",
"name": "BULTOT Hugues Pierre Ghislain",
"niss": null,
"address": "1150 Woluwe-Saint-Pierre, Avenue de l\u0027Horizon 24"
},
"share_class": "nominatives sans mention de valeur nominale",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 61500,
"holder_person_name": "BULTOT Hugues Pierre Ghislain",
"is_subscriber_only": false,
"n_shares_subscribed": 24600,
"amount_subscribed_eur": 61500,
"is_anonymous_silent_partner": false
},
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1969-06-27",
"name": "CASTILLO FERNANDEZ Jose Antonio",
"niss": null,
"address": "1000 Bruxelles, Rue de la Buanderie 18 b3.1"
},
"share_class": "nominatives sans mention de valeur nominale",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 61500,
"holder_person_name": "CASTILLO FERNANDEZ Jose Antonio",
"is_subscriber_only": false,
"n_shares_subscribed": 26137,
"amount_subscribed_eur": 61500,
"is_anonymous_silent_partner": false
},
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1968-11-26",
"name": "MESTDAGH Frank",
"niss": null,
"address": "5537 Anh\u00E9e, Rue Griant, Bioul 1"
},
"share_class": "nominatives sans mention de valeur nominale",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 61500,
"holder_person_name": "MESTDAGH Frank",
"is_subscriber_only": false,
"n_shares_subscribed": 10763,
"amount_subscribed_eur": 61500,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 61500,
"subject_company": {
"kbo": "1027.640.071",
"name_full": "Phoenix Biosciences",
"legal_form": "SNC"
},
"initial_directors": [],
"incorporation_date": "2025-09-12",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | Phoenix Biosciences |